TAVI: PLC Systems launches RenalGuard trial
PLC Systems treats the 1st patient with its RenalGuard in a trial to evaluate the device in patients with acute kidney failure undergoing heart valve replacement procedures.
PLC Systems (PINK:PLCSF) said its RenalGuard device was used in a new clinical trial evaluating the device in treating patients with acute kidney failure undergoing transcatheter aortic valve implantation.
The TAVI procedure, used in patients with faulty aortic valves, can cause complications including acute kidney failure. PLC hopes to show that patients treated with RenalGuard will suffer less from acute kidney failure than those without the renal treatment.